

# Integrative physical oncology

Haralampos Hatzikirou,<sup>1†</sup> Arnaud Chauviere,<sup>1,3†\*</sup> Amy L. Bauer,<sup>2</sup>  
André Leier,<sup>3,4</sup> Michael T. Lewis,<sup>5,6</sup> Paul Macklin,<sup>7,8</sup> Tatiana T.  
Marquez-Lago,<sup>3,4</sup> Elaine L. Bearer<sup>1</sup> and Vittorio Cristini<sup>1,3,9\*</sup>

Cancer is arguably the ultimate complex biological system. Solid tumors are microstructured soft matter that evolves as a consequence of spatio-temporal events at the intracellular (e.g., signaling pathways, macromolecular trafficking), intercellular (e.g., cell–cell adhesion/communication), and tissue (e.g., cell–extracellular matrix interactions, mechanical forces) scales. To gain insight, tumor and developmental biologists have gathered a wealth of molecular, cellular, and genetic data, including immunohistochemical measurements of cell type-specific division and death rates, lineage tracing, and gain-of-function/loss-of-function mutational analyses. These data are empirically extrapolated to a diagnosis/prognosis of tissue-scale behavior, e.g., for clinical decision. Integrative physical oncology (IPO) is the science that develops physically consistent mathematical approaches to address the significant challenge of bridging the nano (nm)–micro ( $\mu\text{m}$ ) to macro (mm, cm) scales with respect to tumor development and progression. In the current literature, such approaches are referred to as multiscale modeling. In the present article, we attempt to assess recent modeling approaches on each separate scale and critically evaluate the current ‘hybrid-multiscale’ models used to investigate tumor growth in the context of brain and breast cancers. Finally, we provide our perspective on the further development and the impact of IPO. © 2011 John Wiley & Sons, Inc. *WIREs Syst Biol Med* 2011 DOI: 10.1002/wsbm.158

## INTRODUCTION

A wealth of qualitative evidence links disease progression with tumor morphology, invasion, and metastasis. Brain tumors are the 10th most

common tumor in adults and the 7th leading cause of death in developed countries. Glioblastoma is the most deadly, with life expectancy of 15–18 months after diagnosis. Brain tumors are graded, not staged. The WHO classification system, despite being almost uniformly accepted, is an imperfect grading system, since tumors within the WHO grade IV classification have drastically different prognosis, from a high 5-year survival for medulloblastoma to short-term mortality for glioblastoma.<sup>1</sup> The new WHO approach incorporates and interrelates morphology, with a few cytogenetic, molecular genetic, and immunologic markers, in an attempt to construct a cellular classification.<sup>2</sup> For instance, diagnostic morphology for grade IV includes cellular atypia and nuclear pleomorphism, necrosis, vascular or endothelial proliferation, and pseudo-palisading. Diffuse infiltration of stroma is always present, with tumors cells as far as several centimeters away from the radiologically identified lesion. Similarly in breast cancer, the second most prevalent cancer among women in the United States, pathologic criteria are broadly defined and widely varying response to therapy and outcomes for tumors with the same

†These authors contributed equally to this work.

\*Correspondence to: vcristini@salud.unm.edu, achauviere@salud.unm.edu

<sup>1</sup>Department of Pathology, University of New Mexico, Albuquerque, NM, USA

<sup>2</sup>Los Alamos National Laboratory, Los Alamos, NM, USA

<sup>3</sup>STMC, University of New Mexico, Albuquerque, NM, USA

<sup>4</sup>Okinawa Institute of Science and Technology, Okinawa, Japan

<sup>5</sup>Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA

<sup>6</sup>Department of Radiology, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA

<sup>7</sup>Division of Mathematics, University of Dundee, Dundee, UK

<sup>8</sup>Center for Applied Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

<sup>9</sup>Department of Chemical and Biomedical Engineering, University of New Mexico, Albuquerque, NM, USA

DOI: 10.1002/wsbm.158

diagnosis are common.<sup>3</sup> For example, approximately 80% of breast cancers are diagnosed as ‘no special type’ and are lumped together as ‘infiltrating ductal carcinoma’. Yet these tumors are associated with differing morphological features, gene expression profiles,<sup>4,5</sup> responses to therapy, and patient survival.

In the last 10 years, a large amount of new molecular data has emerged from genome-wide association studies of glioblastoma<sup>6,7</sup> and breast cancer.<sup>8,9</sup> From a clinical point of view, broad histopathologic criteria are used to diagnose these tumors, made on fixed specimens, and prognose actual tumor behavior in the living patient that evolves over time. However, the variability of tumor progression and response to therapy demonstrate that more details about individual tumor are critically needed. For instance, the abundance of microscale phenotype data (cell architecture, mitotic rates, etc.) has not been *integrated* into a comprehensive picture of individual tumor behavior. The *gap* between the microscopic underlying processes of cancer cell behavior and the emerging macroscopic tumor growth and progression must be urgently addressed. This includes the need for a better understanding of the interplay between a tumor and its micro-/macro-environment, which influences growth and treatment response and remains poorly understood.<sup>10,11</sup>

A main *objective* of integrative physical oncology (IPO) is to employ mathematical modeling to develop biophysically sound mechanistic links among the multimodal, multidimensional, and multiscale phenomena involved in tumor progression. Mathematical modeling provides rigorous tools to link and quantify the multifactorial connections between variables governing growth, prognosis, and treatment. The resulting unified model of tumor behavior can provide a deeper fine-grained diagnosis, thus leading to more accurate and definitive predictions of treatment response and survival. To date, models have been developed at each of the relevant scales and were partially successful in answering specific questions on tumor development. In the following, we briefly review and discuss some of these recent efforts at the subcellular, cellular, and tissue scales applied to breast and brain cancers. We chose breast tumors [ectoderms with a basement membrane (BM) that should be penetrated] and brain tumors (neuroectoderms with direct invasion into stroma) because of their differences and similarities, as a support to introduce key issues and illustrate concepts that we discuss in the paper. Our choice of these specific cancer types is also motivated because they present different challenges for modelers and are, to our knowledge, the only cancer types that have been investigated from an

IPO perspective. On the basis of our critical analysis of these recent modeling efforts at each scale and the recent attempts at hybrid multiscale modeling, which reveals crucial issues, we discuss our conceptual view of IPO and outlines its future directions and applications, including the novel approach of ‘mathematical pathology’.

## SUBCELLULAR SCALE

Tumors arise initially from a single cell. A normal cell (a.k.a. cell-of-origin) transforms step-by-step into a tumor cell because of various genetic and epigenetic changes.<sup>12–15</sup> The ways in which this happens are manifold, as are the biological components and signaling pathways involved.<sup>12</sup> Among the best studied key molecules/pathways directly or indirectly associated with cancer are Ras/ERK, PI3K/Akt/mTOR, VEGF, Rb, p53, and Wnt, each of which has been intensively targeted by drug development efforts.

Depending, in particular, on the cell-of-origin, its potency, the number and kinds of carcinogenic mutations, tumors can develop largely varying characteristics with respect to their cellular morphology, proliferative activity, and therapeutic response.<sup>15</sup> Moreover, populations of cells within a single tumor are often heterogeneous, suggesting distinct dynamics at the single cell level.<sup>15</sup> Their concerted action, together with influences from the microenvironment, gives rise to a specific tumor phenotype. Hence, identification and understanding of the tumor-specific biochemical mechanisms at the subcellular scale can greatly aid researchers in the development of tailored therapeutic strategies.

## Key Issues and Modeling Efforts

Accurate modeling and simulation of single cell dynamics is a challenging task because of the vast number of biochemical species involved, the often heterogeneous distribution of molecules inside the cell, and the discrete and stochastic nature of biochemical reactions. Moreover, the intracellular environment is geometrically complex and involves a plethora of correlated spatiotemporal processes that are, *per se*, multiscaled. Typical timescales of interest range between microseconds (molecular diffusion) to weeks/years (cell lifespan), while spatial scales range from angstroms or nanometers (molecules) to tens of micrometers (cell size).

When choosing an appropriate modeling description, one has to decide (for each scale) if a given subcellular system can be best described

as discrete or continuous, spatially homogeneous or heterogeneous, deterministic or stochastic, and how hybrid or multiscale modeling approaches can be constructed starting from the single cell level.<sup>16</sup> Aside from equation-based models (ordinary, stochastic, partial, and delay differential equations), accelerated simulation algorithms based on master equations, such as delay<sup>17,18</sup> or spatial Monte-Carlo,<sup>19</sup> or even highly resolved particle-tracking methods<sup>20</sup> have become popular for spatiotemporal modeling of intracellular processes. Recently, agent-based modeling (ABM) and simulation methods have also shown great promise for understanding phenomena in biology and medicine.<sup>21</sup>

Alternative approaches that have been used in the context of cancer modeling are rule-based models and Boolean networks. Rule-based modeling involves the representation of molecules as structured objects and their interactions as rules for transforming the attributes of these objects.<sup>22</sup> Boolean network models have been suggested for problems where no quantitative information on reaction rates and initial conditions is available. Among other applications, Boolean networks have been used for modeling receptor crosstalk in endothelial cells, mapping environmental cues to cells.<sup>23</sup>

During the last decade, many modeling efforts have addressed specific signaling pathways, including the aforementioned carcinogenic and related types.<sup>24–27</sup> However, many models in the literature assume a closed system, often devoid of the crosstalk between pathways. Moreover, most models follow a mechanistic, continuous deterministic approach and assume spatial homogeneity in the distribution of participating molecules. Inevitably, this ignores any potential discrete or stochastic effects, while there has been increasing evidence that spatial heterogeneities significantly affect the dynamics.<sup>28,29</sup>

There are several issues that, to the best of our knowledge, have not yet been considered. For instance, a single mutated allele (as opposed to mutation of both alleles) in tumor-suppressor genes may be sufficient for cancer progression.<sup>30</sup> Logically, the mix of mutated and nonmutated copies of a gene might introduce additional complexity, as each allele would express different products. Also, there are many known epigenetic effects related to various types of cancer.<sup>31–34</sup> For instance, low level DNA methylation in tumor cells (as compared to DNA methylation levels in normal cells) was one of the first epigenetic abnormalities observed in human cancer cells.<sup>14</sup> Changes in the epigenome are also linked to a higher metastatic potential in many tumor types.<sup>14</sup>

## From Intracellular to Tissue Level

Tumor cells, like normal cells, communicate with their local environment. Each cell receives a multitude of signals from its surroundings, processes these signals with a complex network of highly intertwined pathways, and in turn signals to other cells. The latter usually happens via direct contact or over short distances by secreting signaling molecules. In tumor cells, these signals can affect cell–cell and cell–ECM (extracellular matrix) interactions, eventually causing loss of cellular adhesion, induction of angiogenesis, cell migration, tissue invasion, and metastasis. At this stage, the initially local single cell defect has developed into a multicellular process at the tissue, organ, or even organism scale.

## CELLULAR SCALE: A CASE STUDY

Cancer progression and development can be viewed as a sequence of functional traits or phenotypes that cells have to acquire if a neoplasm (benign tumor) is to become an invasive and malignant cancer. Subcellular mechanisms and their corresponding microenvironmental feedbacks control the cell's phenotype, which in turn determines tumor behavior. Thus, cell interactions with the local microenvironment, which includes neighboring cells of same and different types and various components of the surrounding tissue, play a major role in cancer progression. Various modeling techniques have been developed to describe the characteristics and behaviors of individual cells interacting with their microenvironment. These approaches are typically based on treating cells as discrete, interacting entities and correspond to cellular automata (CA), cellular Potts models (CPM), agent-based models, and immersed boundary models, depending on the level of complexity used to represent cells, i.e., from single points to deformable bodies. We refer the reader to the recent review, Ref 35, for details on these methods.

Rather than trying to present an extensive review, we use recent applications to ductal carcinoma *in situ* (DCIS), a significant precursor to invasive breast carcinoma whose growth is confined to the duct lumen, to illustrate key issues in cell-scale cancer modeling, as a support of our discussion on the future requirement and challenges of IPO. DCIS is commonly detected as a subtle pattern of calcifications in mammograms; mammograms are also used with other imaging modalities to plan surgical resection (lumpectomy) of the tumor, but multiple surgeries are often required to fully eliminate DCIS. This highlights deficiencies in current surgical planning and, more generally, an insufficient

understanding of the biophysical underpinnings of DCIS.

## Key Issues and Modeling Efforts

### *Stem/Progenitor Cell Hierarchies*

In DCIS, proliferation, apoptosis, and stem/progenitor cell differentiation cell dynamics are dysregulated, leading to cell overproliferation.<sup>36</sup> In Ref 37, a cellular automaton model—where the cells are uniformly sized and restricted to a Cartesian mesh—was developed to study the impact of stem cell-progenitor cell hierarchies on DCIS development, finding that these hierarchies increase genetic heterogeneity and accelerate DCIS evolution.

### *Cell Polarization and Complex Microarchitectures*


Noncancerous breast duct epithelial cells are polarized: integrins on the cells' basal surfaces adhere to ligands on the BM, E-cadherins on the cells' lateral sides adhere to E-cadherin on neighboring cells, and the cells' apical sides are typically devoid of adhesion receptors. When cells lose adhesion to the BM, they commit *anoikis*, a specialized type of apoptosis that is triggered by loss of integrin signaling (Ref 38 and references therein). In DCIS, cell polarization and anoikis are dysregulated, and complex microstructures (e.g., micropapillary and cribriform DCIS) can form in the viable rim. In Refs 39–42, an immersed boundary model of DCIS was developed, where each cell's morphology is evolved under the balance of adhesive and fluid mechanical forces. The authors explicitly modeled the cells' polarized adhesion, with functional ties to proliferation and apoptosis via simplified signaling models. The model produced complex micropapillary-like structures (Figure 1, left). The work in Ref 43 developed a lattice-free, agent-based

model of DCIS, where each cell is a sphere that moves under the balance of adhesive and repulsive forces. Cells were assumed to adhere to at most two neighbors (as a simplified phenomenological model of polarization). The model reproduced micropapillary- and cribriform-like microstructures (Figure 1, right). The authors hypothesized that the cribriform subtype arises from micropapillary DCIS when overproliferation causes micropapillae to connect around 'microlumens'. In these modeling efforts, mechanistic cell-scale models that recapitulate complex known tumor microstructures have given key insight on their biomechanical underpinnings.

These results could be improved by more accurately modeling the cells' individual morphologies, which is possible using a cellular Potts model. In a CPM, each cell occupies a finite, simply connected set of grid points in a Cartesian mesh, which enables the model to capture and characterize dynamic changes in a cell's size, shape, and location. This multicellular system is updated by a Monte-Carlo technique to reduce the total system energy, which includes separate terms to model motility, growth, and cell–cell and cell–BM adhesion. Key signaling events (e.g., anoikis) can readily be implemented in each cell. See Refs 44–46 and the references therein, and the *Hybrid-Multiscale Models* section below. The cellular Potts approach has been used to model the three-dimensional (3D) avascular tumor growth response to microenvironmental survival signals,<sup>44</sup> and also to elucidate the impact of cell–ECM interactions on glioma invasion in nonuniform ECM structures.<sup>45</sup>

### *Hypoxia and Invasion*

Growth substrates (particularly oxygen and glucose) can only reach a (necessarily avascular) DCIS tumor by diffusion; as the tumor grows, oxygen gradients form, leading to hypoxia and eventually (comedo) necrosis. Over long timescales, microcalcifications can form in



**FIGURE 1** | Mathematical modeling of complex ductal carcinoma *in situ* (DCIS) microstructures: (Left) An immersed boundary model produced micropapillary-like DCIS structures when cell polarization was assumed. (Reprinted with permission from Ref 42. Copyright 2007 Hindawi Publishing Corporation). (Right) An agent-based model predicted that polarized DCIS cells form micropapillary structures (iterations 200 and 500) that merge into cribriform-like structures (iterations 800 and onward). (Reprinted with permission from Ref 43. Copyright 2010 Elsevier)


the necrotic debris (Ref 38 and references therein). In Refs 47–49, a cellular automaton model was employed to investigate the impact of hypoxia, glycolysis (a form of anaerobic metabolism), and acidosis (a buildup of acidic glycolysis byproducts) on DCIS invasion. The authors found that sustained hypoxia can select for aggressive DCIS subclones that colonize the viable rim and eventually invade the stroma, thus providing new hypotheses on DCIS invasion.

### Necrotic Core/Calcification Biomechanics

The authors in Refs 38,50–52 recently developed an agent-based model of DCIS, which included detailed necrotic cell volume changes and the first model of calcification. After a careful calibration to the biological literature and patient data, the model predicted that the mechanical separation between the viable rim and the necrotic core arises because of the fast timescales of necrotic cell swelling and lysis. The authors determined that necrotic cell lysis acts as a major biomechanical stress relief; as a result, much of the proliferative cell flux is directed toward the duct center, rather than along the duct. An additional consequence is the formation of an ‘age-structured’ necrotic core, with the oldest (often calcified) material in center and the newest material on the perinecrotic boundary (Figure 2). These results are consistent with patient histopathology (see Ref 38). The model also predicted that DCIS tumors grow linearly at 7–10 mm/year and that the tumor’s mammographic (calcification) size linearly correlates with the tumor’s pathologic size. Both these results are in excellent quantitative agreement with the clinical literature. These results show that rigorously calibrated mechanistic cell-scale models can explain macro-scale observations in DCIS histopathology and radiology and may eventually assist surgical planning by augmenting mammography with model-predicted surgical margins.

### Integration with Multiscale Modeling Frameworks

As the intermediate scale between the molecular (intracellular) and tissue scales, cell-scale models will play an essential role in emerging multiscale modeling frameworks,<sup>53,54</sup> in which the intracellular scale can be directly incorporated into cellular-scale models by including a molecular-scale model in each cell. Cell-scale effects are currently incorporated into tissue-scale models through hybrid techniques (see following section). Equally important is that cell-scale models can be directly compared with clinical measurements, making them ideal for calibrating multiscale frameworks. Using the rigorous agent model calibration



**FIGURE 2** | Patient-calibrated ductal carcinoma *in situ* (DCIS) simulation. After calibration to patient immunohistochemistry and morphometric measurements, an agent model correctly reproduced the solid-type DCIS microstructure: an 80- $\mu\text{m}$  viable rim with most frequent proliferation (green cells) on the outermost edge and apoptosis (red cells) throughout, a mechanical separation at the perinecrotic boundary, and an ‘age-structured’ necrotic core with increasing pyknosis (nuclear degradation) and calcification (progression indicated by the shade of red) toward the duct center. The bright red central region is a radiologically detectable casting-type microcalcification. These features are seen in patient hematoxylin and eosin stained histopathology, including the mechanical gap (increased by tissue dehydration), increasing pyknosis toward the duct center and central calcium phosphate microcalcifications.

developed in Ref 38 along with a novel upscaling argument, the authors of Ref 50 calibrated a steady-state continuum model of DCIS volume to immunohistochemical and morphometric data from several patients. The model accurately predicted the overall tumor volume in 14 of the 17 cases, thus demonstrating the potential for cell-scale models to rigorously calibrate multiscale frameworks to molecular and cellular data, by dynamic upscaling procedures.

### TISSUE SCALE

To a large extent, the tissue scale is the clinically relevant scale of the disease. It is the scale at which first symptoms are noticed, e.g., by finding an abnormal mass during physical examination (organ level) or by discovering elevated amount of chemicals such as tumor markers or abnormal immune system proteins in blood test (systemic level). It is also the scale at which secondary imaging investigations are performed, such as magnetic resonance imaging (MRI) or mammography for breast tumor. MRI is particularly helpful in determining macroscopic characteristics of tumors, such as the approximate size and morphology, which are necessary information for tumor grade classification and more accurate treatment planning. The tissue scale is the relevant one for surgical and chemotherapy and radiotherapy planning.

### Key Issues and Modeling Efforts

At the tissue scale, a tumor is not only the macroscopic manifestation of the underlying processes at smaller scales but also the result of its interactions with the surrounding healthy tissue. While the molecular

and cellular mechanisms result in carcinogenesis, tumor growth also depends in a complex manner on biochemical and biophysical transport where continuum modeling (e.g., mechanics) is required. On an individual patient basis, cancer modeling at the tissue scale may translate into an improved understanding of the timescale of tumor growth, and consequently, provide answers to practical clinical questions such as: where and what to resect; where to target and how to optimize radiotherapy; how drugs, antibodies, or small molecules are transported through tissues into neoplastic cells; and how this transport affects therapeutic response.

Modeling and computational approaches for macroscopic tumor growth require the description of the dynamics of billions of tumor cells. Such a description is possible only by averaging single cell behaviors into macroscopic quantities that characterize observables of tissue growth, such as tumor size and growth rate, cell density, mechanical pressure, and stress. At this level of description, approaches can be split into cell population dynamics and continuum models. Both approaches are based on *phenomenological* functional relationships that describe particular macroscopic features in terms of model parameters, most of which are not direct measurable quantities at the cellular scale but account for average cell behavior at the tissue scale. Typical timescales range from days (e.g., for *in vivo* growth of multicellular spheroids) to months (mean life expectancy is 12–15 months for glioma) and years (breast cancer is often a 20-year long disease process), while spatial scales are of the order of millimeter and centimeter or more when considering the whole human body.


Cell population dynamics models are used when no clear spatial structure emerges or it is not taken into account. This may be the case when the system of interest looks very well mixed with respect to its various components (e.g., different cell populations) or in the absence of pertinent morphological and structural tissue data. Such systems are considered spatially homogeneous and are modeled by selecting the most appropriate description among the large variety of differential equations, i.e., ordinary, delay, stochastic, and age-structured. Examples of work are the modeling of carcinogenesis<sup>55</sup> and the interactions between a malignant tumor and the immune system.<sup>56</sup> The assumption of spatial homogeneity can also be used to investigate the fate of anticancer drug delivered within the whole organism, when the description of the complex geometry would be too challenging and would not increase the understanding of drug fate, e.g., for pharmacological control based on pharmacokinetics and pharmacodynamics.<sup>57</sup>

Continuum models are based on conservation laws of physics and use deterministic partial differential equations as a spatiotemporal modeling framework to account for spatial heterogeneities in both tumors and their microenvironment. One particular interest of these models is their ability to include mechanical effects on tumor growth, as for breast<sup>58</sup> and brain<sup>59</sup> tumors described as an elastic soft tissue. Tumors can also be represented by more complex material with dissipative regimes generated by cell reorganization.<sup>60</sup> All these models have in common the need for biophysical constitutive laws to describe tumor mechanical properties.<sup>61</sup>

A simplified approach consists in describing tumor growth by a mass balance equation where mass changes occur in time and space due to tumor cell proliferation and migration. This simplified description by partial differential reaction-diffusion equations (RDE) has been used for gliomas, in combination with pretreatment MRIs to quantify patient-specific cell proliferation and invasion rates that are prognostically significant,<sup>62</sup> and to simulate surgical resection, radiotherapy, and chemotherapy.<sup>63</sup> More sophisticated models including the effect of vascularization and angiogenesis have also been developed by using RDEs to investigate therapeutic strategies<sup>64</sup> or multiphase-mixture modeling to predict drug response in breast cancer.<sup>65</sup> In the multiphase-mixture representation,<sup>66</sup> tumor and host regions are described as a mixture of multiple solid phases (tumor and stroma cells, ECM, substrates, etc.) and the interstitial fluid. This approach is flexible enough to account for interaction forces generated by the extracellular matrix<sup>67</sup> and computationally efficient to predict growth and morphological changes of tumor spheroids that result from heterogeneities of the microenvironment (Figure 3).<sup>68</sup>

## Integration with Multiscale Modeling Frameworks

One major criticism to the tissue level models is that direct calibration of parameters at this scale is not possible in general and relies on fitting, which makes the models mostly unreliable outside the range of parameters over which they have been calibrated. Other important issues to consider are as follows: since individual cell activity can ultimately be responsible for generation of a macroscopic structure, such as a mammary ductal tree or a breast tumor,<sup>69</sup> how can a tissue model be informed from single cell activity? Vice-versa, since mechanical and other phenomena in a tissue may lead, at the individual cell level, to phenotypic adaptation generated by physical forces such



**FIGURE 3** | Three-dimensional computer model predicts gross morphologic features of a growing glioblastoma. Viable (light gray) and necrotic (dark gray) tissue regions and vasculature (mature blood-conducting vessels in red; new nonconducting vessels in blue) are shown. The simulations reveal that the morphology is affected by neovascularization, vasculature maturation, and vessel cooption. (Reprinted with permission from Ref 68. Copyright 2007 Elsevier)

as hydrostatic pressure and shear stress,<sup>70</sup> how can we account for tissue-scale information in a cell-scale model? These issues require the development of *multiscale* mathematical tools capable of bridging the gap between scales and thus arguably the current gap in oncology.


## HYBRID-MULTISCALE MODELS

Because of the intrinsic multiscale nature of cancer, a deeper understanding requires the development of models that integrate and combine the phenomena spanning the multiple scales involved. Hybrid continuum-discrete implementations, which typically seek to combine the best of the tissue (continuum) and cellular (discrete) scale approaches while minimizing their limitations, are a very promising modeling approach. Although other definitions exist in the field, the authors of Ref 53 proposed recently to divide hybrid modeling into ‘composite hybrid’ and ‘adaptive hybrid’ approaches. Many published methods belong to the first category and claim to be multiscale because they are based on a hybrid description of the tumor components, typically by using a discrete representation of the various cell populations and continuum fields to describe cell substrates (e.g., nutrients, oxygen, and diffusible factors). These models *incorporate processes at multiple scales* but can hardly capture the nontrivial interactions among scales that are responsible for the growth of malignant tissue. The second category is

an emerging topic in the community of mathematical and computational oncology and to our knowledge is made of only two recent studies (highlighted below) that provide an implementation of discrete and continuum descriptions to simultaneously account for single cell and tissue behaviors, and the interactions between the two scales.

In a recent study,<sup>71,72</sup> the authors treat tumor’s necrotic and quiescent areas as a continuous viscoelastic medium coupled to an ABM of tumor cells located at the tumor periphery where proliferative activity is artificially constrained to occur. The ABM allows for the detailed description of single cells by including their intercellular dynamics and is coupled to the continuum description via a balance of forces between single cells and the tumor (quiescent) tissue. Another group developed a hybrid continuum-discrete implementation that combines an ABM for invasive tumor cells, which is directly coupled to the continuum model used for the tumor bulk by balancing transfers of mass and momentum between the two representations.<sup>73–75</sup> There is also indirect coupling between the continuum and discrete tumor representations through the (reaction-diffusion) equations for cell substrates (e.g., oxygen, glucose) and the ECM since both types of cell representation take up nutrients and growth factors, and remodel the extracellular matrix (Figure 4). Rules are posed to describe the conditions for switching between discrete and continuum representations without artificially imposing where such transitions occur. Briefly, discrete cells are released in hypoxic regions to model the epithelial-to-mesenchymal transition, and discrete cells are converted back to the continuum description when their local population exceeds a threshold.

Although both examples above utilize coexisting continuum and discrete tumor cell representations, the overall approach is still phenomenological since the functional relationships between the parameters and variables used at the continuum level involve quantities that are not directly obtained from the cell scale. Further, the rules for determining whether to convert discrete cells to the continuum representation and vice-versa are empiric. Therefore, it is our opinion that the future modeling and computational challenges of IPO should be concerned with developing a new class of *hybrid-multiscale models* based on: (1) different representations to describe the same quantity of interest at different scales, e.g., using cell density at the tissue scale and a number of discrete cell agents at the cellular scale; (2) direct calibration/validation of the cell-scale parameters and equations from individual measurements; and finally (3) rigorous upscaling techniques to ‘close’ the continuum equations at the



**FIGURE 4** | Individual (discrete) palisading glial cells invasion into vascularized tissue. (a) Computer simulation from a hybrid-multiscale model showing palisading cells escaping from the perinecrotic region (dark gray) by upregulating motility and downregulating adhesion and proliferation. This phenotypic change is driven by hypoxia as the selective evolutionary force (see *Discussion* section). Cell migration occurs via chemotaxis and haptotaxis in response to gradients of oxygen and extracellular matrix (ECM) concentration, respectively. Brown: conducting vessels; yellow: nonconducting. (b) Background shows distribution of oxygen concentration ( $n = 1$  in vascularized tissue and  $n < 1$  in the tumor white/yellow perinecrotic region). (Reprinted with permission from Ref 73. Copyright 2009 American Association for Cancer Research)

tissue scale, thus providing an accurate description of the processes thereby.

The multiple-scale processes involved in tumor angiogenesis also present mathematical and computational challenges even though vasculature formation and remodeling involve a smaller ensemble of (endothelial) cells compared to a whole 3D tumor. As an example of angiogenesis modeling that bridges molecular and multicellular phenomena, a novel approach was introduced in Refs 76 and 77 that reduced the number of phenomenological rules needed. At the cellular scale, a cellular Potts model was implemented to describe cellular growth, proliferation, migration, apoptosis, and restructuring of the extracellular matrix. This cellular model was integrated with a partial differential equation model describing the spatiotemporal evolution of VEGF and with a Boolean network model of intracellular signaling that considered VEGF specific receptors, integrin receptors, and signaling initiated by cell–cell contact (see also *Further Reading* section).

## DISCUSSION: INTEGRATIVE PHYSICAL ONCOLOGY

From our arguments, the reader may realize that the development of predictive tumor growth models involves major mathematical challenges. While theoreticians and experimentalists have developed numerous models to investigate tumor development and growth and the underlying processes at various scales, mathematical multiscale models have only

recently attempted to bridge the gap between the various spatiotemporal scales in the quest for predictive models of cancer. The heart of the matter lies in the *difficulty of deriving a mathematical framework that provides the tools for a biophysically sound approach that is also physically consistent across the scales*, a requirement of utmost importance for IPO. Indeed, such a framework would allow, through upscaling techniques, the use of directly measurable quantities at the cellular scale to inform the model parameters at the tissue scale, in principle making multiscale models predictive because the data used for calibration exist at a different scale (and are of different nature) from those used for validation.

The field of IPO must address complex mathematical issues to appropriately model tumor development and better understand the emergence of macroscopic tumor characteristics as a result of molecular and cellular phenomena. However, IPO may have a broader impact by also producing novel biological hypotheses on previously overlooked phenomena. Biologists tend to consider the single cell as the *Fundamental Tissue Unit* (cFTU, where ‘c’ stands for cell). This reductionistic approach has proven very helpful in improving the current understanding of subcellular and cellular processes that lead to normal and pathologic tissue development. However, based on the principles of evolution, it is well accepted that progression in cancer is not only a consequence of intrinsic instability of the cell genome but also the result of extrinsic influences acting as selective forces upon tumor cells. Therefore, we argue that there must exist another fundamental tissue unit, herein named




mFTU (where 'm' stands for microenvironmental). The mFTU spans a length scale across which physical transport of substrates (e.g., oxygen diffusion) occurs and generates selective stress that ultimately leads to the prevalence of one phenotype over another. We believe that a typical order of magnitude of the mFTU should be the length scale at which transport phenomena lead to the establishment of tangible concentration gradients of substrates (oxygen) and we suggest considering at least 10 cell-lengths as a characteristic mFTU length scale (i.e., an associated volume of approximately  $10^3$  cells or  $100^3 \mu\text{m}^3$ ). This length scale will of course change depending on the problem.

The need for an extended FTU to understand the role of the environment on normal and malignant tissue development is already recognized by the biological community, e.g., Refs 78 and 79. However, the complexity of coupled multifactorial processes is prohibitive for a systematic experimental exploration of the phenomena at the mFTU scale, a statement exacerbated when one considers *in vivo* investigations, for which costs, in terms of time and financial support, as well as technical challenges, are strongly limiting factors. Via multiscale mathematical methods, IPO offers a framework that allows for a systematic approach to investigate the mFTU that can also be used to sharpen further experimental focus. Indeed, IPO proposes a mathematical representation of the system of interest (i.e., a very small tissue sample) in which through parameter-sensitivity perturbation studies: (1) the influence of each component can be tested independently and experimentally validated and (2) the behavior of the entire system can be theoretically predicted to provide specific directions for future experimental investigations. Then, predictions at the tissue level would be the result of the coupled nonlinear dynamics of a mosaic of interacting mFTUs, the behavior of each of them being understood as a single piece of the puzzle and assembled via biophysical laws and boundary conditions.

One example of the necessity of the mFTU as the minimal scale of importance is cancer invasion, e.g., tumor fingering into surrounding host tissue, which occurs due to the interplay of subcellular processes leading, among other malfunctions, to dysregulated cell proliferation and adhesion. As shown in Refs 68 and 80, these cell-scale (cFTU) effects are mediated and driven by physical transport phenomena at the mFTU scale, e.g., diffusion gradients of cell substrates pointing away from the tumor bulk, and modulate the features of the invasion process; but cFTU effects alone would not lead to organized and effective (clinically relevant) invasion of the surrounding stroma, but

rather to trivial random walks of cells in the neighborhood of the tumor/stroma interface with no average direction.<sup>68</sup> A second example is tumor resistance to chemotherapy. A traditional approach that focuses only on drug treatment failure at the molecular and cellular (cFTU) levels typically and significantly underestimates resistance *in vivo* because it cannot account for processes at larger scales such as the phenomenon of 'diffusion barriers' associated with limited drug and cell substrate penetration into the bulk of a tumor.<sup>81</sup> By extending the scale of investigation to the mFTU and considering drug (and oxygen) transport by diffusion through the tissue, it has been shown that chemo-resistance is significantly driven by the environment and often to an extent larger than the intrinsic resistance of single cells,<sup>65</sup> thus leading to *in vivo/in vitro*  $\text{IC}_{50}$  ratios significantly larger than one.<sup>82</sup> Our final example is the investigation of stem cell niches and their role in breast cancer development. From a purely biological point of view, the functional definition of a niche is a set of microenvironmental components (e.g., ECM, signaling molecules, blood vessels) and biological processes (e.g., juxtacrine and paracrine cell signaling) that regulate stem cell behavior. From a physical point of view, we suggest reconsidering the definition of niche within the context of mFTU, so that regulatory effects of the physical transport processes of oxygen and other species on stem cell behavior may be properly accounted for.

A clinical implication of the mFTU concept in the context of IPO lies in the definition and use of histopathologic criteria to diagnose and classify (brain and breast) tumors. These criteria are based on the analysis of small parts of tumor specimens (biopsies) and aim to help pathologists formulate prognosis of tumor progression, in other words, to extrapolate the spatiotemporal behavior of the whole tumor from a small tissue sample. From a physical point of view, as we emphasize above, the macroscopic tumor features result from the complex dynamics at the mFTU level, which suggests a minimal size necessary for biopsies to capture the physical transport phenomena. Multiscale modeling would allow for the construction of a 'functional mapping' from a range of histopathological data of phenotypic and stromal properties into predicted macroscopic tumor features of translational relevance such as growth rate, fingering growth rate, drug response, etc., thus producing a new set of mathematical pathologic criteria. A simplified example of such an approach is the recent work by Macklin,<sup>50</sup> in which the underlying physics of transport across the mFTU accurately connects immunohistopathology measurements from



**FIGURE 5** | Validation of model predictions against pathology-determined ductal carcinoma *in situ* (DCIS) tumor sizes. Surgical tumor size versus parameter  $A$  that is related to the ratio of tumor apoptotic and mitotic indices in the breast ducts. The dotted curve represents the theoretical predictions by a continuum model. Symbols are DCIS tumor size measurements from individual patient histopathology and are subclassified by their grade. The shaded region indicates the standard deviation in the measurement of  $A$  in individual duct. (Reprinted with permission from Ref 50. Copyright 2010 Cambridge University Press)

biopsies to patient-specific translational quantities such as the surgical volume of breast tumors (Figure 5). In doing so, the authors demonstrated that the size of breast tumors does not correlate with grade, but rather with a specific mathematical functional of both mitotic and apoptotic indices in the breast ducts. Hence, we claim that IPO may have a major impact

via the identification of *robust* predictors of tumor progression based on molecular-scale data,<sup>73</sup> which might not require multiple time-point measurements from patients, thus helping bridge the gap discussed at the beginning of this paper through feasible incorporation within the current clinical practice. This is the foundation of *mathematical pathology*.

## ACKNOWLEDGMENTS

We acknowledge the NIH for support through the Physical Sciences in Oncology Center grants 1U54CA143837 and 1U54CA143907 (VC), the Integrative Cancer Biology Program grant 1U54CA149196 for the Center for Systematic Modeling of Cancer Development (VC, ML, AC), and finally NINDS NS062184, NS046810, NIGMS GM47368, and P50GM085273 (ELB). We also acknowledge the National Science Foundation (NSF) for support under grant DMS-0818104 (VC, AC).

All authors contributed revisions on the entire paper. HH and AC contributed to the overall design, formulation, and critical discussion of the concepts in the manuscript and wrote the manuscript except for specific sections as described below. AB wrote the paragraphs on Boolean network and rule-based models, cellular Potts models, and angiogenesis. TML and AL wrote the section ‘Sub-cellular scale’. ML and ELB contributed to the critical discussion and the writing of the biological and translational concepts in Introduction and Discussion. PM wrote the section ‘Cellular Scale’. VC originated the overall design and contributed formulation and critical discussion of the concepts in the manuscript.

## REFERENCES

1. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. *Brain Pathol* 1993, 3:255–268.
2. Cunliffe CH, Fischer I, Parag Y, Fowkes ME. State-of-the-art pathology: new WHO classification, implications, and new developments. *Neuroimaging Clin N Am* 2010, 20:259–271.
3. Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. *J Clin Oncol* 1999, 17:1442–1448.
4. O'Brien KM, Cole SR, Tse C-K, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina breast cancer study. *Clin Cancer Res* 2010, 16:6100–6110.
5. Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz J, He X, Perou C. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. *Breast Cancer Res* 2010, 12:R68.
6. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor J, Hanash SM. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. *Cancer Res* 2001, 61:6885–6891.
7. Vitucci M, Hayes DN, Miller CR. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. *Br J Cancer* 2010, 104:545–553.
8. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. *Proc Natl Acad Sci U S A* 2005, 102:3738–3743.
9. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bitner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, et al. Gene-expression profiles in hereditary breast cancer. *N Engl J Med* 2001, 344:539–548.
10. Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis G, Gillies RJ. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1 $\alpha$  using PX-478. *Neoplasia* 2005, 7:475–485.
11. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. *Nature* 2001, 411:375–379.
12. Bronchud MH, Foote M, Giaccone G, Olopade O, Workman P, eds. *Principles of Molecular Oncology*. 3rd ed. NJ: Humana Press Inc.; 2008.
13. Croce CM. Oncogenes and cancer. *N Engl J Med* 2008, 358:502–511.
14. Robertson KD. DNA methylation and human disease. *Nat Rev Genet* 2005, 6:597–610.
15. Visvader JE. Cells of origin in cancer. *Nature* 2011, 469:314–322.
16. Burrage K, Burrage P, Leier A, Marquez-Lago TT, Nicolau DV. Stochastic simulation for spatial modelling of dynamic processes in a living cell. In: Koepl H, Setti G, di Bernardo M, Densmore D, eds. *Design and Analysis of Bio-molecular Circuits*. New York: Springer; 2011.
17. Leier A, Marquez-Lago TT, Burrage K. Generalized binomial tau-leap method for biochemical kinetics incorporating both delay and intrinsic noise. *J Chem Phys* 2008, 128:205107.
18. Marquez-Lago TT, Leier A, Burrage K. Probability distributed time delays: integrating spatial effects into temporal models. *BMC Syst Biol* 2010, 4:19.
19. Marquez-Lago TT, Burrage K. Binomial tau-leap spatial stochastic simulation algorithm for applications in chemical kinetics. *J Chem Phys* 2007, 127:104101.
20. Andrews SS, Addy NJ, Brent R, Arkin AP. Detailed simulations of cell biology with Smoldyn 2.1. *PLoS Comput Biol* 2010, 6:e1000705.
21. Pogson M, Smallwood R, Qvarnstrom E, Holcombe M. Formal agent-based modelling of intracellular chemical interactions. *Biosystems* 2006, 85:37–45.
22. Blinov ML, Faeder JR, Goldstein B, Hlavacek WS. BioNetGen: software for rule-based modeling of signal transduction based on the interactions of molecular domains. *Bioinformatics* 2004, 20:3289–3291.
23. Bauer AL, Jackson TL, Jiang Y, Rohlf T. Receptor cross-talk in angiogenesis: mapping environmental cues to cell phenotype using a stochastic, Boolean signaling network model. *J Theor Biol* 2010, 264:838–846.
24. Birtwistle MR, Hatakeyama M, Yumoto N, Ogunnaike BA, Hoek JB, Kholodenko BN. Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses. *Mol Syst Biol* 2007, 3:144.
25. Borisov N, Aksamitiene E, Kiyatkin A, Legewie S, Berkhout J, Maiwald T, Kaimachnikov NP, Timmer J, Hoek JB, Kholodenko BN. Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. *Mol Syst Biol* 2009, 5:256.
26. Hsieh M-Y, Yang S, Raymond-Stinz MA, Steinberg S, Vlachos DG, Shu W, Wilson B, Edwards JS. Stochastic simulations of ErbB homo and heterodimerisation: potential impacts of receptor conformational state and spatial segregation. *IET Syst Biol* 2008, 2:256–272.
27. Walker DC, Georgopoulos NT, Southgate J. From pathway to population—a multiscale model of juxtacrine EGFR-MAPK signalling. *BMC Syst Biol* 2008, 2:102.
28. Kholodenko BN, Kolch W. Giving space to cell signaling. *Cell* 2008, 133:566–567.

29. Tian T, Harding A, Inder K, Plowman S, Parton RG, Hancock JF. Plasma membrane nanoswitches generate high-fidelity Ras signal transduction. *Nat Cell Biol* 2007, 9:905–914.
30. Morgan DO. *The Cell Cycle: Principles of Control*. London: New Science Press, Ltd.; 2007.
31. Ballestar E, Esteller M. Epigenetic gene regulation in cancer. *Adv Genet* 2008, 61:247–267.
32. Bell DW. Our changing view of the genomic landscape of cancer. *J Pathol* 2010, 220:231–243.
33. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. *Dev Cell* 2010, 19:698–711.
34. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. *Eur J Pharmacol* 2009, 625:131–142.
35. Rejniak KA, Anderson ARA. Hybrid models of tumor growth. *WIREs Syst Biol Med* 2011, 3:115–125.
36. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, Mohsin SK, O'Connell P, Tsimelzon A, Medina D. Ductal carcinoma *in situ* and the emergence of diversity during breast cancer evolution. *Clin Cancer Res* 2008, 14:370–378.
37. Bankhead A III, Magnuson NS, Heckendorn RB. Cellular automaton simulation examining progenitor hierarchy structure effects on mammary ductal carcinoma *in situ*. *J Theor Biol* 2007, 246:491–498.
38. Macklin P, Edgerton ME, Thompson AM, Cristini V. Patient-calibrated agent-based modelling of ductal carcinoma *in situ* (DCIS): from microscopic measurements to macroscopic predictions of clinical progression. *J Theor Biol*. Submitted for publication.
39. Rejniak KA. An immersed boundary framework for modelling the growth of individual cells: an application to the early tumour development. *J Theor Biol* 2007, 247:186–204.
40. Rejniak KA, Anderson ARA. A computational study of the development of epithelial acini: I. Sufficient conditions for the formation of a hollow structure. *Bull Math Biol* 2008, 70:677–712.
41. Rejniak KA, Anderson ARA. A computational study of the development of epithelial acini: II. Necessary conditions for structure and lumen stability. *Bull Math Biol* 2008, 70:1450–1479.
42. Rejniak KA, Dillon RH. A single cell-based model of the ductal tumour microarchitecture. *Comput Math Methods Med* 2007, 8:51–69.
43. Norton KA, Wining M, Bhanot G, Ganesan S, Barnard N, Shinbrot T. A 2D mechanistic model of breast ductal carcinoma *in situ* (DCIS) morphology and progression. *J Theor Biol* 2010, 263:393–406.
44. Jiang Y, Pjesivac-Grbovic J, Cantrell C, Freyer JP. A multiscale model for avascular tumor growth. *Biophys J* 2005, 89:3884–3894.
45. Rubenstein BM, Kaufman LJ. The Role of Extracellular Matrix in Glioma Invasion: A Cellular Potts Model Approach. *Biophys J* 2008, 95:5661–5680.
46. Shirinifard A, Gens JS, Zaitlen BL, Poplawski NJ, Swat M, Glazier JA. 3D Multi-Cell Simulation of Tumor Growth and Angiogenesis. *PLoS One* 2009, 4:e7190.
47. Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB, Worrall L, Gillies RJ. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. *Br J Cancer* 2007, 97:646–653. PMID: 2360372.
48. Silva AS, Gatenby RA, Gillies RJ, Yunes JA. A quantitative theoretical model for the development of malignancy in ductal carcinoma *in situ*. *J Theor Biol* 2010, 262:601–613.
49. Smallbone K, Gatenby RA, Gillies RJ, Maini PK, Gavaghan DJ. Metabolic changes during carcinogenesis: potential impact on invasiveness. *J Theor Biol* 2007, 244:703–713.
50. Macklin P, Edgerton ME, Cristini V. Agent-based cell modeling: application to breast cancer. In: Cristini V, Lowengrub JS. *Multiscale Modeling of Cancer: An Integrated Experimental and Mathematical Modeling Approach*. New York: Cambridge University Press; 2010, 206–234.
51. Macklin P, Edgerton ME, Lowengrub JS, Cristini V. Discrete cell modeling. In: Cristini V, Lowengrub JS. *Multiscale Modeling of Cancer: An Integrated Experimental and Mathematical Modeling Approach*. New York: Cambridge University Press; 2010, 88–122.
52. Macklin P, Kim J, Tomaiuolo G, Edgerton ME, Cristini V. Agent-based modeling of ductal carcinoma *in situ*: application to patient-specific breast cancer modeling. In: Pham T, ed. *Computational Biology: Issues and Applications in Oncology*. New York: Springer; 2009, 77–112.
53. Deisboeck TS, Wang Z, Macklin P, Cristini V. Multiscale cancer modeling. *Annu Rev Biomed Eng* 2011, 13.
54. Lowengrub J, Frieboes HB, Jin F, Chuang Y-L, Li X, Macklin P, Wise SM, Cristini V. Nonlinear modeling of cancer: bridging the gap between cells and tumors. *Nonlinearity* 2010, 23:R1–R91.
55. Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. *Nat Rev Cancer* 2007, 8:56–61.
56. Eftimie R, Bramson JL, Earn DJD. Interactions between the immune system and cancer: a brief review of non-spatial mathematical models. *Bull Math Biol* 2011, 73:2–32.
57. Clairambault J. Modelling physiological and pharmacological control on cell proliferation to optimise cancer treatments. *Math Model Nat Phenom* 2009, 4:12–67.
58. Pathmanathan P, Gavaghan DJ, Whiteley JP, Chapman SJ, Brady JM. Predicting tumor location by modeling the deformation of the breast. *IEEE Trans Biomed Eng* 2008, 55:2471–2480.

59. Hogue C, Biros G, Abraham F, Davatzikos C. A robust framework for soft tissue simulations with application to modeling brain tumor mass effect in 3D MR images. *Phys Med Biol* 2007, 52:6893–6908.
60. Ambrosi D, Preziosi L. Cell adhesion mechanisms and stress relaxation in the mechanics of tumours. *Biomech Model Mechanobiol* 2009, 8:397–413.
61. Unnikrishnan GU, Unnikrishnan VU, Reddy JN, Lim CT. Review on the constitutive models of tumor tissue for computational analysis. *Appl Mech Rev* 2010, 63:040801.
62. Wang C, Rockhill J, Mrugala M, Peacock D, Lai A, Jusenius K, Wardlaw J, Cloughesy T, Spence A, Rockne R, et al. Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. *Cancer Res* 2009, 69:9133.
63. Eikenberry SE, Sankar T, Preul MC, Kostelich EJ, Thalhauser CJ, Kuang Y. Virtual glioblastoma: growth, migration and treatment in a three-dimensional mathematical model. *Cell Prolif* 2009, 42:511–528.
64. McDougall SR, Anderson ARA, Chaplain MAJ. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. *J Theor Biol* 2006, 241:564–589.
65. Frieboes HB, Edgerton ME, Fruehauf JP, Rose FR, Worrall LK, Gatenby RA, Ferrari M, Cristini V. Prediction of drug response in breast cancer using integrative experimental/computational modeling. *Cancer Res* 2009, 69:4484–4492.
66. Byrne H, Preziosi L. Modelling solid tumour growth using the theory of mixtures. *Math Med Biol* 2003, 20:341–366.
67. Preziosi L, Tosin A. Multiphase modelling of tumour growth and extracellular matrix interaction: mathematical tools and applications. *J Math Biol* 2009, 58:625–656.
68. Frieboes HB, Lowengrub JS, Wise S, Zheng X, Macklin P, Elaine LBD, Cristini V. Computer simulation of glioma growth and morphology. *Neuroimage* 2007, 37:S59–S70.
69. Kordon EC, Smith GH. An entire functional mammary gland may comprise the progeny from a single cell. *Development* 1998, 125:1921–1930.
70. Butcher D, Alliston T, Weaver V. A tense situation: forcing tumour progression. *Nat Rev Cancer* 2009, 9:108–122.
71. Kim Y, Stolarska M, Othmer H. A hybrid model for tumor spheroid growth in vitro. I: theoretical development and early results. *Math Models Methods Appl Sci* 2007, 17(suppl):1773
72. Stolarska M, Kim Y, Othmer H. Multi-scale models of cell and tissue dynamics. *Philos Trans R Soc A* 2009, 367:3525–3553.
73. Bearer EL, Lowengrub JS, Frieboes HB, Chuang YL, Jin F, Wise SM, Ferrari M, Agus DB, Cristini V. Multi-parameter computational modeling of tumor invasion. *Cancer Res* 2009, 69:4493–4501.
74. Frieboes HB, Jin F, Chuang YL, Wise SM, Lowengrub JS, Cristini V. Three-dimensional multispecies nonlinear tumor growth-II: tumor invasion and angiogenesis. *J Theor Biol* 2010, 264:1254–1278.
75. Jin F, Chuang Y-L. Hybrid continuum-discrete tumor models. In: Cristini V, Lowengrub JS. *Multiscale Modeling of Cancer: An Integrated Experimental and Mathematical Modeling Approach*. New York: Cambridge University Press; 2010, 123–152.
76. Bauer AL, Jackson TL, Jiang Y. A cell-based model exhibiting branching and anastomosis during tumor-induced angiogenesis. *Biophys J* 2007, 92:3105–3121.
77. Bauer AL, Jackson TL, Jiang Y. Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis. *PLoS Comput Biol* 2009, 5:e1000445.
78. Bissell M, Aggeler J. Dynamic reciprocity: how do extracellular matrix and hormones direct gene expression? *Prog Clin Biol Res* 1987, 249:251–262.
79. Tanos T, Brisken C. What signals operate in the mammary niche? *Breast Dis* 2008, 29:69–82.
80. Hatzikirou H, Basanta D, Simon M, Schaller K, Deutsch A. “Go or Grow”: the key to the emergence of invasion in tumour progression? *Math Med Biol* 2010.
81. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science* 2009, 324:1457–1461.
82. Sinek JP, Sanga S, Zheng XM, Frieboes HB, Ferrari M, Cristini V. Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. *J Math Biol* 2009, 58:485–510.

## FURTHER READING

Araujo RP, McElwain DLS. A history of the study of solid tumour growth: the contribution of mathematical modelling. *Bull Math Biol* 2004, 66:1039–1091.

Bauer AL. Multi-scale cell-based model to simulate and elucidate the mechanisms controlling tumor-induced angiogenesis. Ph.D. dissertation, University of Michigan, Ann Arbor, MI; 2007.

Bellomo N, Li NK, Maini PK. On the foundations of cancer modelling: selected topics, speculations, and perspectives. *Math Models Methods Appl Sci* 2008, 18:593–646.

Chauvière A, Preziosi L, Verdier C, eds. *Cell Mechanics. From Single Scale-Based Models to Multiscale Modeling*. Boca Raton: Chapman & Hall/CRC Mathematical and Computational Biology; 2010.

Cristini V, Lowengrub JS. *Multiscale modeling of cancer: an integrated experimental and mathematical modeling approach*. Cambridge: Cambridge University Press; 2010.

Edelman LB, Eddy JA, Price ND. *In silico* models of cancer. *WIREs Syst Biol Med* 2009, 2:438–459. doi:10.1002/wsbm.75.

Meier-Schellersheim M, Fraser IDC, Klauschen F. Multiscale modeling for biologists. *WIREs Syst Biol Med*. 2009, 1:4–14. doi:10.1002/wsbm.33.

Osborne JM, Walter A, Kershaw SK, Mirams GR, Fletcher AG, Pathmanathan P, Gavaghan D, Jensen OE, Maini PK, Byrne HM. A hybrid approach to multi-scale modelling of cancer. *Philos Trans A* 2010, 368:5013–5028.

Preziosi L, Tosin A. Multiphase and multiscale trends in cancer modelling. *Math Model Nat Phenom*. 2009, 4:1–11.

Tracqui P. Biophysical models of tumour growth. *Rep Prog Phys* 2009, 72:30.

Verdier C, Etienne J, Duperray A, Preziosi L. Review: rheological properties of biological materials. *C R Phys*. 2009, 10:790–811.